A scientific journal just pulled a 2011 Alzheimer's paper that claimed a specific protein causes memory loss. Neurobiology of Aging retracted the study, which focused on amyloid-β as the culprit behind the disease.
This isn't a one-off situation. Over the past few years, multiple studies supporting the amyloid-β theory have been retracted. Some researchers have even faced fraud indictments over their work in this area.
Here's the bigger problem: despite all the focus on amyloid-β, drugs targeting this protein haven't shown real clinical benefits. That's a massive issue when you consider how much research funding and pharmaceutical development has centered on this single hypothesis.
For anyone working in health tech or AI-driven drug discovery, this is a reminder that scientific consensus can be built on shaky ground. The Alzheimer's field bet heavily on one theory, and it's increasingly looking like the wrong bet.
This matters because AI models trained on flawed research inherit those flaws. If your health AI relies on the amyloid hypothesis, you might be building on a foundation that's crumbling. The retractions suggest we need to look at Alzheimer's through a completely different lens.
